| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Mary Jo Turk | |
| Katelyn T. Byrne | |||
| P2860 | cites work | Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells | Q24530100 |
| Direct evidence to support the role of antigen-specific CD8(+) T cells in melanoma-associated vitiligo | Q77748286 | ||
| Systematized depigmentation in melanoma treated with x-irradiation | Q78791305 | ||
| Role of interleukin-17 in the pathogenesis of vitiligo | Q83097800 | ||
| Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study | Q84270711 | ||
| The Double Strike Hypothesis of the vitiligo pathomechanism: new approaches to vitiligo and melanoma | Q84548892 | ||
| Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma | Q24618690 | ||
| Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens | Q24644442 | ||
| Tumor-specific Th17-polarized cells eradicate large established melanoma | Q24648032 | ||
| Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes | Q24676216 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Mast cell-deficient W-sash c-kit mutant Kit W-sh/W-sh mice as a model for investigating mast cell biology in vivo | Q28506160 | ||
| Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy | Q30305530 | ||
| Mechanisms of spatial and temporal development of autoimmune vitiligo in tyrosinase-specific TCR transgenic mice | Q30433217 | ||
| Deletional self-tolerance to a melanocyte/melanoma antigen derived from tyrosinase is mediated by a radio-resistant cell in peripheral and mesenteric lymph nodes | Q30444006 | ||
| Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG. | Q33586122 | ||
| Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. | Q33730129 | ||
| Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts | Q33730171 | ||
| Th17 cells and activated dendritic cells are increased in vitiligo lesions | Q33889471 | ||
| Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity | Q33912129 | ||
| Features of responding T cells in cancer and chronic infection. | Q33941340 | ||
| gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma | Q34188859 | ||
| Optimization of a self antigen for presentation of multiple epitopes in cancer immunity | Q34537491 | ||
| Prognostic role of antibody reactivity to melanoma | Q34573286 | ||
| Stimulation of the glucocorticoid-induced TNF receptor family-related receptor on CD8 T cells induces protective and high-avidity T cell responses to tumor-specific antigens | Q34634220 | ||
| Autoimmune melanocyte destruction is required for robust CD8+ memory T cell responses to mouse melanoma | Q34876334 | ||
| Multiple pathways to tumor immunity and concomitant autoimmunity | Q35005947 | ||
| Melanocyte-specific immune response in melanoma and vitiligo: two faces of the same coin? | Q35129926 | ||
| Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. | Q35901034 | ||
| Heterogeneity and cell-fate decisions in effector and memory CD8+ T cell differentiation during viral infection | Q36202704 | ||
| Therapeutic implications of autoimmune vitiligo T cells. | Q36292745 | ||
| Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets | Q36347214 | ||
| Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein | Q36365511 | ||
| Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. | Q36368332 | ||
| Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. | Q36371632 | ||
| Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp | Q36375152 | ||
| Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma | Q36376523 | ||
| gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand | Q36401461 | ||
| Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice | Q36403509 | ||
| Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo | Q36490763 | ||
| Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines. | Q36491854 | ||
| Autoantibody responses to melanocytes in the depigmenting skin disease vitiligo. | Q36731840 | ||
| Topical application of bleaching phenols; in-vivo studies and mechanism of action relevant to melanoma treatment | Q36871503 | ||
| Induction of postsurgical tumor immunity and T-cell memory by a poorly immunogenic tumor | Q36930696 | ||
| Harnessing autoimmunity (vitiligo) to treat melanoma: a myth or reality? | Q36958358 | ||
| Melanoma progression despite infiltration by in vivo-primed TRP-2-specific T cells | Q37110386 | ||
| Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects | Q37461129 | ||
| Current remedies for vitiligo | Q37691025 | ||
| Depigmentation: its significance in patients with melanoma | Q38671874 | ||
| Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma | Q39981736 | ||
| Generation and characterization of a therapeutic human antibody to melanoma antigen TYRP1. | Q40003464 | ||
| Human leukocyte antigen-A2-restricted CTL responses to mutated BRAF peptides in melanoma patients. | Q40304048 | ||
| Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particles | Q40349207 | ||
| Vitiligo and malignant melanoma: a significant association? | Q41061172 | ||
| Evidence for immunologic mechanisms in human vitiligo: patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity | Q41437267 | ||
| Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients | Q42065004 | ||
| HLA class II‐restricted recognition of common tumor epitopes on human melanoma cells by CD4+ melanoma‐infiltrating lymphocytes | Q42677926 | ||
| Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma | Q43693202 | ||
| Prognostic significance of autoimmunity during treatment of melanoma with interferon. | Q44019499 | ||
| A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen | Q44432137 | ||
| Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy | Q44532957 | ||
| Should vitiligo be induced in patients after resection of primary melanoma | Q44705294 | ||
| Vaccination-induced autoimmune vitiligo is a consequence of secondary trauma to the skin | Q44769933 | ||
| Vitiligo and Melanoma | Q45243585 | ||
| VITILIGO IN A CASE OF VACCINIA VIRUS-TREATED MELANOMA. | Q45714781 | ||
| Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma | Q46528620 | ||
| Autoimmunity and tumor immunity induced by immune responses to mutations in self | Q46917393 | ||
| Mutations at the W locus affect survival of neural crest-derived melanocytes in the mouse. | Q50520303 | ||
| Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions. | Q51976721 | ||
| Immunological associations of the halo naevus with cutaneous malignant melanoma. | Q53786030 | ||
| Uveitis and vitiligo associated with BCG treatment for malignant melanoma. | Q53842134 | ||
| Malignant melanoma and vitiligo. | Q54739041 | ||
| Skin-Depigmenting Agent Monobenzone Induces Potent T-Cell Autoimmunity toward Pigmented Cells by Tyrosinase Haptenation and Melanosome Autophagy | Q60628789 | ||
| Perilesional vitiligo in melanoma | Q67548989 | ||
| Prognostic significance of hypopigmentation in malignant melanoma | Q69263890 | ||
| Correlation between vitiligo antibodies and extent of depigmentation in vitiligo | Q69664761 | ||
| Vitiligo in patients with metastatic melanoma: a good prognostic sign | Q71105100 | ||
| Malignant melanoma and vitiligo-like leukoderma: an electron microscopic study | Q71105103 | ||
| Anti-tyrosinase antibodies in malignant melanoma | Q71254382 | ||
| The serological analysis of human cancer. Identification of differentiation antigens on melanoma and melanocytes | Q71776566 | ||
| Vitiligo- and melanoma-associated hypopigmentation: a similar appearance but a different mechanism | Q72523065 | ||
| Spontaneous regression of primary malignant melanomas with regional metastases | Q72592753 | ||
| A novel, antigen-presenting function of melanocytes and its possible relationship to hypopigmentary disorders | Q72651347 | ||
| Accumulation of identical T cells in melanoma and vitiligo-like leukoderma | Q73265370 | ||
| P275 | copyright license | Creative Commons Attribution 2.5 Generic | Q18810333 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | melanoma | Q180614 |
| vitiligo | Q180152 | ||
| skin neoplasm | Q18921119 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 684-94 | |
| P577 | publication date | 2011-09-01 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | New perspectives on the role of vitiligo in immune responses to melanoma | |
| P478 | volume | 2 |
| Q55243058 | Advanced Care Provider and Nursing Approach to Assessment and Management of Immunotherapy-Related Dermatologic Adverse Events. |
| Q43025486 | Ccl22 Diverts T Regulatory Cells and Controls the Growth of Melanoma. |
| Q33737498 | Combination immunotherapy for high-risk resected and metastatic melanoma patients |
| Q53039229 | Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study. |
| Q38231601 | Do inflammatory pathways drive melanomagenesis? |
| Q38916814 | Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma |
| Q61802519 | Functionalisation of Virus-Like Particles Enhances Antitumour Immune Responses |
| Q34352772 | Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo |
| Q37718447 | Immunogenicity of targeted lentivectors. |
| Q42610971 | Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-Hu antibodies: A beneficial antitumor immune response going awry |
| Q92220421 | Immunotherapy in metastatic melanoma: a novel scenario of new toxicities and their management |
| Q55053720 | Immunotherapy in mucosal melanoma: a case report and review of the literature. |
| Q37088617 | Inflammatory monocytes are potent antitumor effectors controlled by regulatory CD4+ T cells. |
| Q35627237 | Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma |
| Q64971747 | Management of metastatic cutaneous melanoma: updates in clinical practice. |
| Q26850001 | Melanoma-associated leukoderma - immunology in black and white? |
| Q36339260 | Nectin like-5 overexpression correlates with the malignant phenotype in cutaneous melanoma. |
| Q36505754 | Patterns of response in patients with pretreated metastatic melanoma who received ipilimumab 3 mg/kg in a European expanded access program: five illustrative case reports |
| Q64272394 | Reactive capillary hemangiomas: a novel dermatologic toxicity following anti-PD-1 treatment with SHR-1210 |
| Q42609189 | Regression of metastatic melanoma in a patient by antibody targeting of cancer stem cells |
| Q41010063 | Regression of nevi in a melanoma patient treated with interferon |
| Q40148698 | Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced melanoma |
| Q34386621 | Serum activity of DPPIV and its expression on lymphocytes in patients with melanoma and in people with vitiligo |
| Q28067023 | Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma |
| Q37299271 | Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival |
| Q54985631 | The Pharmacology of T Cell Therapies. |
| Q27008140 | Toxicities of Immunotherapy for the Practitioner |
| Q90140465 | Twelve cases of acneiform eruptions while on anti-CTLA4 therapy |
Search more.